Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin
- 17 Downloads
BDF female mice inoculated with MXT mammary adenocarcinoma were treated for 30 days with microcapsules of the luteinizing hormone-releasing hormone (LH-RH) agonist D-Trp-6-LH-RH (releasing 25µg/day for 30 days), microcapsules of the somatostatin agonist RC-160 (liberating 25µg/day for one month), or the combination of these peptides. Bilateral surgical ovariectomy was performed in one group which served as an additional control. Tumor volume was measured weekly during the treatment period of 30 days. When tumor volume changes in the treated groups were compared to the corresponding changes in controls, the combination of D-Trp-6-LH-RH and RC-160 was the most effective in inhibiting tumor growth and approached the effect of surgical ovariectomy. At the conclusion of the experiment, tumor weights were also measured. All peptide analogs inhibited tumor weight by 42 to 63%. In the D-Trp-6-LH-RH treated group, ovarian weights and uterine weights decreased by 48% and 52%, respectively, as compared to controls. Histologically, the regressive changes in tumors caused by the treatment with RC-160, D-Trp-6-LH-RH and their combination were characterized by the coexistence of apoptosis (programmed cell death) and coagulation necrosis. The transition of apoptosis into coagulation necrosis was a common finding. The term ‘apoptotic index’ is proposed for the ratio of tumorous glands containing apoptotic cells. The apoptotic index was higher in the treated groups than in the control.
Key wordsluteinizing hormone-releasing hormone (LH-RH) MXT mammary tumor D-Trp-6-LH-RH somatostatin analog RC-160 apoptosis programmed cell death
Unable to display preview. Download preview PDF.
- 1.Schally AV, Comaru-Schally AM: Use of Luteinizing Hormone-Releasing Hormone analogs in the treatment of hormone dependent tumors. Semin Reprod Endocrinol 5: 389–398, 1987Google Scholar
- 3.Schally AV, Bajusz S, Redding TW, Zalatnai A, Comaru-Schally AM: Analogs of LH-RH. The present and the future. In: Vickery BH, Luenefeld B: GnRH analogues in cancer and human reproduction. MTP Press, Lancaster/Boston, 1989Google Scholar
- 4.Gonzalez-Barcena D, Rangel-Garcia N, Perez-Sanchez PL, Gutierrez-Damperio C, Garcia-Carrasco R, Comaru-Schally AM, Schally AV: Response of advanced adenocarcinoma of pancreas to D-Trp-6-LH-RH. Lancet ii, 154, 1989Google Scholar
- 10.Redding TW, Fekete M, Schally AV: Direct inhibition of the MT-5 rat mammary tumor cell line by somatostatin analog RC-160. Abstract, Endocrine Society meeting, New Orleans, June, 1988, No. 603, p 171Google Scholar
- 11.Sharoni Y, Basin E, Miinster A, Levy J, Schally AV: Inhibition of growth of human mammary tumor cells by potent antagonists of Luteinizing Hormone-Releasing Hormone. Proc Natl Acad Sci USA 86: 1989, in pressGoogle Scholar
- 12.Gullino PM: The regression process in hormone-dependent mammary carcinomas. In: Iacobelli S,et al.: Hormones and Cancer. Raven Press, New York, 1980, pp 271–279Google Scholar
- 15.Srkalovic G, Szende B, Redding TW, Groot K, Schally AV: Receptors for D-Trp-6-luteinizing hormone-releasing hormone, somatostatin and insulin-like growth factor-I in MXT mouse mammary carcinoma. Proc Soc Exp Biol Med 192: dec 1989Google Scholar
- 17.Redding TW, Schally AV: Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp-6-LH-RH. Proc Natl Acad Sci USA 80: 6509–6512, 1983Google Scholar
- 29.Oates PS, Morgan RGH, Light AM: Cell death (apoptosis) during pancreatic involution after raw soya flour feeding in the rat. Am J Physiol 198: G9-G14, 1986Google Scholar